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Enantiomers of 2,3-dihydro-1,4-benzodioxine derivatives possessing both thrombin and ﬁbrinogen
GPIIb/IIIa binding inhibitory activities were prepared from (R)- and (S)-glycidol as potential dual
antithrombotic compounds. The inﬂuence of chirality and substitution pattern on thrombin inhibition
and on inhibition of ﬁbrinogen binding to GPIIb/IIIa was analyzed. Docking studies were used in an
attempt to rationalize the results. The (S)-isomers of both 2,3-dihydro-1,4-benzodioxine regioisomers at
positions 6 and 7 were found to be better thrombin inhibitors than the corresponding (R)-enantiomers,
whereas we observed that stereochemistry does not display a consistent inﬂuence on ﬁbrinogen GPIIb/
IIIa binding inhibitory activity. Compound 11b, the (S)-isomer of the 6-substituted regioisomer, pos-
sessed the best balanced dual activity, with Ki(thrombin) ¼ 1.67  0.27 mM and IC50(GPIIb/
IIIa) ¼ 0.665  0.26 mM, raising the hope that merging anticoagulant and platelet antiaggregatory ac-
tivities in the same molecule could lead to successful multitarget antithrombotic agents.
 2013 Elsevier Masson SAS. All rights reserved.1. Introduction
Cardiovascular diseases are the main cause of death in devel-
oped countries [1]. Existing anticoagulant and antiplatelet therapy,
despite its importance and effectiveness in the treatment of car-
diovascular diseases, has numerous limitations such as bleeding,
metabolism that differs in different individuals due to genetic
polymorphism, and interaction with other drugs and food [2,3].
During the last decade much effort have been made to design
novel anticoagulant drugs that target the coagulation enzymes
thrombin, factor Xa, factor VII and factor IX, with the aim of
obtaining a simple and satisfactory, orally applicable replacementB, Protein Data Bank; DMAP,
F, N,N-dimethylformamide;
c acid.
þ386 1 4258031.
lj).
son SAS. All rights reserved.for the existing warfarin treatment [4e11]. Ximelagatran, a prodrug
of melagatran, was the ﬁrst oral direct thrombin inhibitor intro-
duced to themarket, however it was withdrawn from themarket in
2006 due to expressed hepatotoxicity [12,13]. Dabigatran etexilate
is a new oral prodrug for the direct thrombin inhibitor dabigatran
(Fig. 1) that entered the market in 2008 for the prevention of blood
clotting following hip or knee surgery, and for the prevention of
stroke in patients with non-valvular atrial ﬁbrillation [14]. Good
progress has also beenmade in the ﬁeld of direct and indirect factor
Xa inhibitors. Rivaroxaban, a recently introduced, highly selective
oral factor Xa inhibitor, promised effectiveness and safety in pre-
venting venous thromboembolism [15]. Other novel factor Xa in-
hibitors include the recently approved apixaban, and idraparinux
that is in the ﬁnal stage of clinical investigation [16].
Platelets play an essential role in the maintenance of hemosta-
sis; they are responsible for clot formation when damage of
endothelium of blood vessels occurs [17]. The platelet glycoprotein
IIb/IIIa antagonists abciximab, eptiﬁbatide and tiroﬁban are potent
antiplatelet agents, and are used to prevent pathological platelet
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Fig. 1. Structures of the clinically used thrombin inhibitor dabigatran, the racemic 1,4-
benzoxazine derivatives [25,30] and the enantiomers of 1,4-benzodioxine derivatives
reported in this paper.
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and those undergoing invasive heart procedures [18].
In clinical practice, an effective prophylaxis and treatment of
thromboembolic diseases, such as deep vein thrombosis, throm-
boembolic stroke, pulmonary embolism and myocardial infarction,
is achieved by using a combination of various antiaggregatory and
anticoagulant drugs [19]. Since the combined use of thrombin in-
hibitors and glycoprotein IIb/IIIa antagonists in the prevention of
cardiovascular diseases has shown additional beneﬁts over treat-
ment directed against thrombin or against platelets alone [20], we
envisaged merging anticoagulant and platelet antiaggregatory ac-
tivity in the same molecule as a promising approach towards novel
multitarget antithrombotic agents [21e25]. Recently, other groups
have reported the preparation of dual anticoagulant/antiplatelet
agents featuring high molecular weight, polysulfated conjugates
[26], in contrast to our dual acting compounds with strongly
overlapping pharmacophores and low molecular weight.
In our previous work on potential dual antithrombotic com-
pounds, combining in one molecule both thrombin inhibitory and
ﬁbrinogen receptor antagonistic activities [24,25], 3,4-dihydro-2H-
1,4-benzoxazine [27] was selected as a suitable scaffold, on the
basis of docking experiments, enabling convenient attachment ofReagents and conditions: a) Et 3N, DMAP, DCM, 0 ºC → rt, 1
Scheme 1. Synthesis ofsubstituents in positions 2, 4, 6 and 7 [25]. The benzamidinemoiety,
a typical P1 group of thrombin inhibitors and an arginine mimetic
of the RGDmotif [28], was attached at position 2 of the benzoxazine
core, while P3 benzyl and carboxylic acid moieties, required for
thrombin inhibition and GPIIb/IIIa binding [29], were bound at
positions 6 or 7 of the 1,4-benzoxazine skeleton (Fig. 1). Molecular
modeling studies predicted 7-isomers to be better thrombin in-
hibitors while 6-isomers were expected to possess better inhibition
of ﬁbrinogen GPIIb/IIIa binding, as was later conﬁrmed in biological
assays [25]. Focusing on optimization of the P3 part, with a com-
bination of different aromatic and carboxylate group moieties, we
succeeded in preparing well-balanced dual compounds with
thrombin Ki values and IC50 values for inhibition of ﬁbrinogen
binding to platelet GPIIb/IIIa in the high nanomolar/low micro-
molar ranges [30]. Replacement of the highly basic benzamidine
moiety with the less basic [1,2,4] triazolo[4,3-b]pyridazine-6-yl
group resulted in loss of both thrombin inhibitory and ﬁbrinogen
receptor antagonistic activities [31], showing the importance of the
benzamidine group for binding to both targets. The failure to ach-
ieve better afﬁnities of the designed compounds for thrombin and
ﬁbrinogen receptor demonstrates the difﬁculty in reaching a com-
promise that would meet the constraints imposed by both binding
sites.
When designing multiple ligands with highly overlapping
pharmacophores, balancing activities for both targets is demand-
ing, so all structural information is of the utmost value [32e35]. In
the present work we report a 1,4-benzodioxine series of enantio-
meric compounds that combine, in the same molecule, highly
overlapping pharmacophores of thrombin inhibitors and ﬁbri-
nogen receptor antagonists (Fig.1). They resulted from replacement
of the 1,4-benzoxazine core by a 1,4-benzodioxine scaffold [36],
a privileged heterocyclic skeleton applied in the design of selective
a1 adrenoceptor antagonists [37], antioxidants [38,39], radical
scavenging compounds [40e42], hypolipidemic [43] and anti-
inﬂammatory agents [44,45]. In order to explore the signiﬁcance
of chirality and regioisomerism in balancing the activity of the new
1,4-benzodioxine compounds at both targets, and thanks to the
commercial availability of both (R)- and (S)-glycidol (required for
enantioselective synthesis of the parent 2-substituted benzodiox-
ine cores), we prepared both enantiomers of the benzodioxine 6-
and 7-regioisomers and studied the effects of chirality and regioi-
somerism on binding the resulting potential dual antithrombotic
compounds to thrombin and platelet ﬁbrinogen receptor.2. Chemistry
The synthesis of target 1,4-benzodioxine enantiomers 11ae
d from 4-nitrocatechol is presented in Schemes 1 and 2. The
strongly electronegative nitro group in 4-nitrocatechol enabled
effective control of the regioselectivity in construction of the 1,4-h; b) NaH, DMF, 80 ºC, 2h; c) Na2CO3, DMF, 60 ºC, 2h.
compounds 5aed.
Reagents and conditions: a) 4-cyanophenol, PPh3, DIAD, THF, reflux, 48h; b) H2, Pd/C
(10%), 25 bar, rt, 1h; c) benzaldehyde, MeOH, mol. sieves, rt, 12h, then NaBH4, 1h; d) 
EtOCOCOCl, Et3N, DCM, rt, 2h; e) HCl(g), EtOH, 0 ºC (30 min) → rt, 24h, then 
CH3COONH4, 24h; f) 1M LiOH, THF/MeOH, rt, 1h.
Scheme 2. Synthesis of compounds 10aed and 11aed.
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6- and 7-nitro isomers, respectively [46]. Thus, using a modiﬁed
published procedure for the synthesis of the racemates [47], the
reaction of 4-nitrocatechol with (R)- and (S)-(2-tosyloxymethyl)
oxirane (3b and 3a), in the presence of potassium carbonate in
N,N-dimethylformamide afforded enantiomers of (7-nitro-2,3-
dihydro-1,4-benzodioxin-2-yl)methanol (5d and 5c), whereas
the reaction of 4-nitrocatechol with 3a or 3b, using sodium hy-
dride as a base, gave (R)- and (S)-6-nitro isomers 5a and 5b
(Scheme 1). Both nitro isomers of the (R)- and (S)-series were
reacted with 4-hydroxybenzonitrile under Mitsunobu conditions
to give ethers 6aed, which were reduced in the next step to
amines 7aed, using catalytic hydrogenation over palladium onTable 1
Biological activity of 1,4-benzodioxine derivatives 10aed and 11aed: the inhibition of ser
GPIIb/IIIa.
Compound Substitution R0 * Ki (mM)
Thrombin
10a 6 Et R 1.65  0.20
10b 6 Et S 0.436  0.037
10c 7 Et R 0.675  0.099
10d 7 Et S 0.0778  0.005
11a 6 H R 5.18  1.15
11b 6 H S 1.67  0.27
11c 7 H R 2.69  0.36
11d 7 H S 0.266  0.03
a Selectivity for thrombin vs. trypsin.
b Selectivity for thrombin vs. factor Xa.
c Compounds were also tested for inhibition of ﬁbrinogen binding to aVb3 receptor ancharcoal. These were benzylated, using benzaldehyde and sodium
borohydride, and the resulting N-benzylamines 8aed acylated
with ethyl oxalyl chloride to give compounds 9aed. Upon Pinner
reaction they afforded esters 10aed which, after alkaline hydro-
lysis with lithium hydroxide in methanol/tetrahydrofuran, gave
the enantiomeric carboxylic acids 11aed (Scheme 2). We tried to
develop an HPLC method for determining the enantiomeric purity
of products 5e11, but succeeded only with compounds 8aed for
which an enantiomeric excess >95% was obtained. The non-
racemizing conditions in the last two reaction steps and con-
sistent optical rotation values of the products allow the conclusion
that the enantiomeric excess of compounds 10aed and 11ae
d remained higher than 95%.ine proteases thrombin, factor Xa, trypsin, and the inhibition of ﬁbrinogen binding to
IC50 (mM)
Trypsin [selectivity]a FXa [selectivity]b GPIIb/IIIac
0.644  0.089 [0.39] 2.15  0.18 [1.30] >200
0.283  0.044 [0.65] 1.51  0.37 [3.46] >200
0.894  0.097 [1.32] 0.637  0.44 [0.95] >200
0.210  0.026 [2.71] 2.70  0.15 [35.9] >200
1.55  0.22 [0.30] 5.19  0.61 [1.30] 1.21  0.32
0.463  0.093 [0.28] 1.96  0.17 [1.17] 0.665  0.26
1.37  0.029 [0.51] 1.27  0.13 [0.47] 17.6  3.0
0.267  0.049 [1.00] 5.08  0.57 [19.1] 42.6  5.3
d none of them showed binding in the test system (IC50(aVb3) > 200 mM).
M. Ilic et al. / European Journal of Medicinal Chemistry 62 (2013) 329e3403323. Biological results
Compounds 10aed and 11aed, comprising enantiomers of the
6- and 7-isomers, were tested for inhibition of thrombin and, in
order to assess their selectivity for related serine proteases, also for
inhibition of factor Xa and trypsin. Additionally, they were tested
for inhibition of ﬁbrinogen binding to GPIIb/IIIa. The results are
presented in Table 1. The general structureeactivity relationship
which was observed in the 1,4-benzoxazine series can also be seen
in the case of the 1,4-benzodioxine series. Esters 10aedwere found
to be more potent thrombin inhibitors than the corresponding
carboxylic acids 11aed, but they lacked ﬁbrinogen GPIIb/IIIa
binding activity (IC50 > 200 mM). Compounds bearing a P3 moiety
in position 6 (11aeb) displayed more pronounced ﬁbrinogen GPIIb/
IIIa binding inhibitory activity (IC50 0.66 and 1.21 mM), while
compounds bearing a P3 moiety at position 7 exhibited more
pronounced thrombin inhibitory activity (Ki ¼ 0.078e2.69 mM).
While compounds 10aed and 11aed were not selective towards
two similar serine proteases, trypsin and factor Xa, the compound
with the most potent thrombin inhibitory activity (10d) was found
also to be the most selective. As demonstrated in Fig. 1, compound
11b, the (S)-isomer of the 6-substituted regioisomer, possessed the
best balanced dual activity (Ki(thr) ¼ 1.67  0.27 mM, IC50(GPIIb/
IIIa) ¼ 0.665  0.26 mM). Compound 10d, the (S)-isomer of the
7-regioisomer, is the most potent thrombin inhibitor, with
Ki(thr) ¼ 77.8  5.0 nM, and compound 11b, ((S)-isomer of the 6-
regioisomer) has the most potent ﬁbrinogen GPIIb/IIIa binding
inhibitory activity, with IC50(IIb/IIIa) ¼ 665  260 nM. This demon-
strates that, in the development of dual antithrombotic compounds
based on the 1,4-benzodioxine scaffold, optimizing ﬁbrinogen re-
ceptor activity is a more difﬁcult task than optimizing thrombin
inhibition.
The (S)-isomers of the 6- and 7-series were found to be better
thrombin inhibitors than the (R)-isomers. Overall, these results are
comparable with those for the 1,4-benzoxazine analogues. The
racemic 1,4-benzoxazine derivative substituted at position 6
showed higher activity on both targets (Ki(thr) ¼ 0.62  0.10 mM,
IC50(GPIIb/IIIa) ¼ 2.8  1.5 mM), while the racemic 1,4-benzoxazine
derivative substituted at position 7 had more pronouncedFig. 2. Compounds 11a (R-isomer, left) and 11b (S-isomer, right) dockedthrombin inhibitory activity (Ki(thr) ¼ 0.19  0.02 mM, IC50(GPIIb/
IIIa) ¼ 39  18 mM) [26]. When considering eudismic ratios, the
results in Table 1 demonstrate that, in the case of esters 10aed in
the 6-regioisomer series, the (S)-isomer is 3.8 times more potent
and, in the 7-regioisomer series, 8.7 times more potent thrombin
inhibitor than corresponding (R)-isomer. Similar results are seen in
the case of acids 10aed where, in 6-substituted compounds, the
(S)-isomer is 3.1 times more potent and, in the 7-substituted
compound, 10.1-fold more potent as a thrombin inhibitor. Stereo-
chemistry does not appear to have such a consistent inﬂuence on
ﬁbrinogen GPIIb/IIIa binding inhibitory activity. In the case of the 6-
substituted compound, the (S)-isomer 11b is 1.8 times more potent
than the (R)-isomer 11a, while in case of 7-substituted compounds
the (R)-isomer 11c is 2.4 timesmore potent than the (S)-isomer 11d.
It can thus be concluded that, in the 1,4-benzodioxine series, the
(S)-6-isomers offer the best opportunities for optimization towards
balanced dual acting compounds.
4. Docking studies
In an attempt to rationalize the differences in the binding af-
ﬁnities of (R)- and (S)-enantiomers for thrombin and ﬁbrinogen
receptor, we performed docking of compounds 11a and 11b ‒ both
enantiomers of the more balanced 6-regioisomer docked to the
thrombin active site and to the binding site of GPIIb/IIIa are
depicted in Fig. 2. Given the similarity of our compounds to dabi-
gatran, the crystal structure of the dabigatranethrombin complex
(PDB: 1KTS) [48] was used for docking experiments. Compounds
11a and 11b bind to the thrombin active site in a similar manner to
dabigatran but the conﬁguration at chiral centers slightly in-
ﬂuences the difference in their binding modes. The distance be-
tween the C-atoms of the Asp189 carboxylate and the amidine
group is 3.9 Å and 4.0 Å for 11a and 11b, and two hydrogen bonds
connect the amidine hydrogens and carboxylate oxygen atoms.
Additional hydrogen bonds of 1.98 Å and 2.0 Å between the ben-
zamidine and the Gly219 backbone for the two compounds are
observed. The 2,3-dihydro-1,4-benzodioxine scaffold is located in
the S2 binding pocket and the benzyl group reaches into the lip-
ophilic S3 binding pocket, with the P3 carboxylate stretchingto thrombin active site (top) and GPIIb/IIIa binding site (bottom).
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adjacent to the chiral carbon of 3,4-dihydro-1,4-benzodioxine are
oriented differently in the two enantiomers. The distance between
the oxygen of the methyleneoxy group and the Ser195 OH group
(OeHO) is 3.1 Å in 11b and 3.6 Å in 11a. The carbon atom of the
methylenoxy groups adjacent to the chiral center is the atom that
differs most in its positioning in 11a and 11b ‒ by 1.92 Å. In 11b, the
methylene group is closer to the protein surface while, in 11a, it
points outwards from the thrombin surface.
The analysis of the binding modes of 11a and 11b docked in the
binding site of GPIIb/IIIa (using PDB: 2VDM ‒ the only published
crystal structure of GPIIb/IIIa in a complex with a low molecular
weight RGD mimetic) [49] shows that the compounds take an
extended conformation. The carboxylic acid moiety occupies an
identical location in 11a and 11b, making electrostatic interactions
with the Mg2þ atom and hydrogen-bonding to the amide proton of
Asn215 of the b3 subunit of the GPIIb/IIIa. The phenyl rings of 11a
and 11b also occupy identical positions, making hydrophobic in-
teractions with Tyr122 of the b3 subunit. The methylenoxy groups
and the benzamidine moieties of 11a and 11b occupy slightly dif-
ferent positions. The Ala218 of the b3 subunit makes, with its
methyl group, hydrophobic interactions with the exocyclic meth-
ylenoxy group of the ligand (distances of 4.2 Å for 11b and 5.5 Å for
11a) and polar interactions of its C]O group with the exocyclic
ether oxygen of the ligand (2.9 Å for 11b and 3.3 Å for 11a). Further,
positioning of the benzamidine moiety, which forms hydrogen
bonds with Asp224 and the Phe160 from the aIIb subunit of the
GPIIb/IIIa, and hydrophobic interactions with Tyr190, Phe231, and
Phe191 of the aIIb subunit, differs between the R- and S-isomers by
0.94 Å difference in the position of the carbon atom of the amidine
moieties of 11a and 11b. The docking experiments thus show better
binding interactions of 11b than that of 11a to platelet ﬁbrinogen
receptor (GPIIb/IIIa).
In summary, the measured activities and analysis of the docking
positions of 11a and 11b at the two targets lead to the conclusion
that the conﬁguration at the chiral center, and the consequent
different positioning of the methylenoxy moiety, accounts, at least
partly, for the difference in potency of the two enantiomers.
Whereas the methylenoxymoiety situated in close proximity to the
chiral center is required for ﬂexibility of the molecule (compounds
10ae11d adopt a bent shape in the thrombin active site and
extended conformations in the ﬁbrinogen receptor-binding site),
this could also explain the low eudismic ratios resulting from the e
CH2Oe group imposed molecular ﬂexibility that diminishes the
difference between the binding conformations of two enantiomers
at a particular target.
5. Conclusion
A novel 1,4-benzodioxine enantiomeric series of compounds
have been prepared that act both as thrombin inhibitors and as
ﬁbrinogen GPIIb/IIIa binding inhibitors. The inﬂuence of chirality
and regioisomerism on their thrombin inhibitory and ﬁbrinogen
GPIIb/IIIa binding inhibitory activities has been analyzed. The dif-
ferences in potency of isomers and observed eudismic ratios can be
explained in terms of the docking poses of the two stereoisomers.
Unfortunately, we were not able to observe antithrombotic action
of this series of compounds in in vivo model of venous thrombosis
in rat, indicating that their potencies on both targets are still too
weak to be measured in vivo. The attempt to balance thrombin
inhibition and ﬁbrinogen GPIIb/IIIa binding inhibitory activities on
the one hand and to achieve lower nanomolar Ki (thrombin) and
IC50 (GPIIb/IIIa) values on the other ‒ which could result in in vivo
antithrombotic activity ‒ remains a viable, but highly demanding
challenge in the search for effective dual antithrombotic drugs.6. Experimental section
6.1. General
Chemicals were obtained from Acros, Aldrich Chemical Co. and
Fluka and used without further puriﬁcation. Analytical TLC was
performed on silica gel Merck 60 F254 plates (0.25 mm), using
visualization with ultraviolet light. Column chromatography was
carried out on silica gel 60 (particle size 240e400 mesh). Melting
points were determined on a Reichert hot stagemicroscope and are
uncorrected. 1H NMR and 13C NMR spectra were recorded on
a 400 MHz Bruker AVANCE III NMR spectrometer (1H NMR at
400.13 MHz and 13C NMR at 100.61 MHz) and on a Bruker Avance
DPX300 spectrometer (1H NMR at 300MHz, 13C NMR at 75 MHz) in
DMSO-d6 solution, with TMS as internal standard. 13C NMR spectra
were assigned using gradient COSY, HSQC and HMBC experiments.
The following abbreviations were used to describe peak splitting
patterns wherever appropriate: br ¼ broad, d ¼ doublet,
dd ¼ doublet of doublet, t ¼ triplet, q ¼ quartet, and m ¼multiplet.
IR spectra were recorded on a PerkineElmer 1600 FT-IR spec-
trometer. Microanalyses were performed on a PerkineElmer C, H, N
Analyzer 240 C. Analyses indicated by the symbols of the elements
were within 0.4% of the theoretical values. Mass spectra were
obtained using a VG-Analytical Autospec Q mass spectrometer.
Optical rotations were measured on a PerkineElmer 1241 MC
polarimeter. Reverse phase HPLC was performed on an Agilent
Technologies HP 1100 instrument with G1365B UVevis detector
(254 nm), using an Eclipse Plus C18 column 5 mm (4.6  150 mm)
at ﬂow rate of 1 mL/min. The eluent was a mixture of 0.1% TFA in
water (A) and methanol (B) and the gradient was 40% B to 80% B
in 15 min. Chiral HPLC analyses were performed on a JASCO
ChromPass Software Version 1.8 with JASCO UV-2075 UVevis de-
tector (244 nm), using a Chiralcel OJ-H 5 mm 4.6  250 mm column
at ﬂow rate of 1 mL/min. Compounds were separated under iso-
cratic conditions using as eluent amixture of 60% n-hexane and 40%
ethanol. All the compounds reported in this paper were>95% pure.
Esters 10aed were puriﬁed by reverse phase column chromatog-
raphy, using a Flash Puriﬁcation System ISOLERA. The eluent was
a mixture of 0.1% TFA in water (A) and methanol (B) and the gra-
dient was 40% B to 80% B in 30 column volumes.
6.2. Synthesis of (R)-glycidyl tosylate (3b)
To a solution of (S)-glycidol (5.50 g, 74.24 mmol), triethylamine
(8.26 g, 81.66 mmol) and 4-(dimethylamino)pyridine (2%, 181 mg,
1.48 mmol) in 60 mL dichloromethane at 0 C, tosyl chloride
(14.15 g, 74.24 mmol) was added and the mixture was stirred at
room temperature for 3 h with formation of a white precipitate.
Dichloromethane (40 mL) was added and the mixture was subse-
quently washed with 100 mL 5% aq. K2CO3, 100 mL 1 M HCl, and
100mLwater. The organic layer was dried over Na2SO4, ﬁltered and
evaporated to dryness. The crude product (15.56 g colourless oil,
92% yield) was used in the next step without further puriﬁcation;
[a]D ¼ 16.7 (c ¼ 0.46, CHCl3), lit.: [50] [a]D ¼ 17.0 (c ¼ 2.83,
CHCl3); 1H NMR (300 MHz, CDCl3): d (ppm) 2.47 (s, 3H, CH3), 2.61
(dd, J¼ 4.8, 2.5 Hz,1H, CH2O), 2.83 (t, J¼ .4 Hz,1H, CH2O), 3.16e3.24
(m, 1H, CH), 4.0 (dd, J ¼ 11.4, 6.0 Hz, 1H, CH2OS), 4.27 (dd, J ¼ 11.4,
3.5 Hz, 1H, CH2OS), 7.37 (d, J ¼ 8.1 Hz, 2H, AreH3, AreH5), 7.82 (d,
J ¼ 8.1 Hz, 2H, AreH2, AreH6).
6.3. Synthesis of (S)-glycidyl tosylate (3a)
To a solution of (R)-glycidol (4.00 g, 54.00 mmol), triethylamine
(6.01 g, 59.50 mmol) and 4-(dimethylamino)pyridine (2%, 132 mg,
1.08mmol) in 50mLdichloromethane at 0 C, tosyl chloride (10.30 g,
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perature for 1 h. During stirring a white precipitate was formed. The
reaction mixture was subsequently washed with 100 mL 5% aq.
K2CO3, 100 mL 1 M HCl, and 100 mL water. The organic layer was
dried over Na2SO4, ﬁltered and evaporated to dryness. The crude
product (11.63 g colourless oil, 95% yield) was used in the next step
without further puriﬁcation; [a]D ¼ þ16.3 (c ¼ 0.57, CHCl3), lit.: [51]
[a]D ¼ þ17.5 (c ¼ 2.13, CHCl3); 1H NMR (300 MHz, CDCl3): d (ppm)
2.47 (s, 3H, CH3), 2.61 (dd, J¼4.8, 2.5Hz,1H,CH2O), 2.81e2.85 (m,1H,
CH2O), 3.17e3.24 (m, 1H, CH), 3.98 (dd, J ¼ 11.4, 6.0 Hz, 1H, CH2OS),
4.27 (dd, J ¼ 11.4, 3.5 Hz, 1H, CH2OS), 7.37 (d, J ¼ 8.1 Hz, 2H, AreH3,
AreH5), 7.83 (d, J ¼ 8.1 Hz, 2H, AreH2, AreH6).
6.4. Synthesis of (R)-(6-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)
methanol (5a)
To a suspension of NaH (60% dispersion, 120 mg, 1.5 mmol) in
5mL DMFat 0 C, 4-nitrocatechol (310mg, 2.00mmol) in 1mL DMF
was added carefully. The mixture was stirred at 0 C for 30 min
(until gas formation ceased) and then a solution of (S)-glycidyl
tosylate (502 mg, 2.20 mmol) in 1 mL DMF was added. The reaction
mixture was stirred at room temperature for 30 min and then
heated at 80 C for 2 h. Upon cooling, the mixture was poured onto
15 mL water. The mixture was extracted with 3  20 mL diethyl
ether. The combined organic phases were dried over Na2SO4, ﬁl-
tered and evaporated to dryness. The crude product obtained was
puriﬁed by column cromatography (petrolether:ethyl acetate 1:1)
to give 178 mg (42%) of pale yellow crystals; mp 112e114 C;
[a]D ¼ þ87.61 (c ¼ 0.57, CHCl3); 1H NMR (300 MHz, CDCl3):
d (ppm) 1.91 (t, J ¼ 6.20 Hz, 1H, OH), 3.86e4.04 (m, 2H, CH2OH),
4.09e4.28 (m, 1H, CH), 4.33e4.47 (m, 2H, CH2O), 6.94e7.08 (m, 1H,
AreH8), 7.75e7.90 (m, 2H, AreH5, AreH7).
6.5. Synthesis of (S)-(6-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)
methanol (5b)
Toa suspensionofNaH (60%dispersion,120mg,1.5mmol) in5mL
DMF at 0 C, 4-nitrocatechol (310 mg, 2.00 mmol) in 1 mL DMF was
added. Themixturewas stirred at 0 C for 30min (until gas formation
ceased) and then a solution of (R)-glycidyl tosylate (502 mg,
2.20mmol) in1mLDMFwasadded. The reactionmixturewas stirred
at room temperature for 30 min and then heated at 80 C for 2 h.
Upon cooling, themixturewaspouredonto15mLwater. Themixture
was extracted with 3  20 mL diethyl ether. The combined organic
phases were dried over Na2SO4, ﬁltered and evaporated to dryness.
The crude product obtained was puriﬁed by column cromatography
(petrolether:ethyl acetate¼ 1:1) to give 212mg (50%) of pale yellow
crystals; mp 112e114 C; [a]D ¼ 86.6 (c ¼ 0.51, CHCl3); 1H NMR
(300MHz, CDCl3): d (ppm)1.91 (t, J¼ 6.20Hz,1H,OH), 3.85e4.04 (m,
2H, CH2OH), 4.10e4.25 (m, 1H, CH), 4.33e4.46 (m, 2H, CH2O), 6.95e
7.04 (m, 1H, AreH8), 7.76e7.88 (m, 2H, AreH5, AreH7).
6.6. Synthesis of (R)-(7-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)
methanol (5c)
A suspension of 4-nitrocatechol (310 mg, 2.00 mmol), (S)-gly-
cidyl tosylate (545 mg, 2.40 mmol) and K2CO3 (663 mg, 4.80 mmol)
in 5 mL DMF was heated at 60 C for 2 h. The mixture was poured
onto 15 mL water and extracted with 3  20 mL diethyl ether. The
combined organic phases were subsequently washed with
3 20mL 10% aq. K2CO3, 20 mLwater and 20mL brine. The organic
layer was dried over Na2SO4, ﬁltered and evaporated to dryness.
The crude product obtainedwas puriﬁed by column cromatography
(petrolether:ethyl acetate ¼ 1:1) to give 191 mg of pale yellow
crystals (45%); mp 117e119 C; [a]D¼þ59.72 (c¼ 0.5 in CHCl3), lit.:[52] þ65.5 (c ¼ 0.58, 96% EtOH); 1H NMR (300 MHz, CDCl3):
d (ppm) 1.94 (t, J ¼ 6.21 Hz, 1H, OH), 3.84e4.08 (m, 2H, CH2OH),
4.12e4.28 (m, 1H, CH), 4.28e4.49 (m, 2H, CH2O), 6.94e7.02 (m, 1H,
AreH5), 7.74e7.87 (m, 2H, AreH6, AreH8).
6.7. Synthesis of (S)-(7-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)
methanol (5d)
A suspension of 4-nitrocatechol (310 mg, 2.00 mmol), (R)-gly-
cidyl tosylate (545 mg, 2.40 mmol) and K2CO3 (663 mg, 4.80 mmol)
in 5 mL DMF was heated at 60 C for 2 h. The mixture was poured
onto 15 mL water and extracted with 4  20 mL diethyl ether. The
combined organic phases were subsequently washed with
3 20 mL 10% aq. K2CO3, 20 mLwater and 20mL brine. The organic
layer was dried over Na2SO4, ﬁltered and evaporated to dryness.
The crude product obtainedwas puriﬁed by column cromatography
(petrolether:ethyl acetate ¼ 1:1) to give 180 mg of yellow crystals
(43%); mp 117e119 C; [a]D ¼ 61.6 (c ¼ 0.5 in CHCl3); 1H NMR
(300 MHz, CDCl3): d (ppm) 1.93 (t, J ¼ 6.19 Hz, 1H, OH), 3.86e4.04
(m, 2H, CH2OH), 4.13e4.27 (m, 1H, CH), 4.30e4.47 (m, 2H, CH2O),
6.93e7.03 (m, 1H, AreH5), 7.75e7.86 (m, 2H, AreH6, AreH8).
6.8. (R)-4-((6-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)methoxy)
benzonitrile (6a). General procedure for synthesis of compounds
6aed
The benzodioxine alcohol 5a (2.80 g, 13.26 mmol) was dissolved
in anhydrous THF (50 mL). Under argon ﬂow and with ice/water
cooling, 4-cyanophenol (1.74 g, 14.59 mmol) and triphenylphos-
phine (6.96 g, 26.52 mmol) were added. Diizopropyl azodicarbox-
ylate (DIAD) (5.36 g, 26.52 mmol) dissolved in 15 mL anhydrous
THF was added dropwise at 0 C. The solution was stirred for
30 min at 0 C, and then heated to reﬂux for 48 h. The mixture was
evaporated to dryness and the crude product was puriﬁed by
recrystallization from MeOH to give 2.15 g (52%) of 6a as pale yel-
low crystals; mp 159e162 C; [a]D ¼ þ83.4 (c ¼ 0.5 in CDCl3); 1H
NMR (400 MHz, DMSO-d6): d (ppm) 4.28 (dd, J ¼ 11.8, 7.2 Hz, 1H, 3-
CH2), 4.39 (dd, J ¼ 11.1, 5.7 Hz, 1H, CH2O), 4.46 (dd, J ¼ 11.1, 3.7 Hz,
1H, CH2O), 4.58 (dd, J ¼ 11.8, 2.5 Hz, 1H, 3-CH2), 4.77e4.85 (m, 1H,
2-CH), 7.13e7.22 (m, 3H, AreH8, AreH2’, AreH6’), 7.77e7.84 (m, 4H,
AreH5, AreH7, AreH3’, AreH5’); 13C NMR (101 MHz, DMSO-d6):
d (ppm) 64.4 (C-3), 66.5 (CH2O), 72.2 (C-2), 103.4 (C-40), 112.7 (C-7),
115.6 (C-20, C-60), 117.6, 117.7 (C-5, C-8), 119.0 (CN), 134.2 (C-30, C-50),
141.1 (C-6), 142.7 (C-4a), 148.8 (C-8a), 161.4 (C-10); HRMS (ESI) m/z
calcd for C16H13N2O5 [Mþ H]þ 313.0824, found 313.0830; IR (KBr, v,
cm1): 2222, 1605, 1522, 1471, 1347, 1252, 1174, 839; HPLC: 100%, tr
16.0 min; Anal. (C16H12N2O5) C, H, N.
6.9. (S)-4-((6-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)methoxy)
benzonitrile (6b)
Synthesized from 5b (1.17 g, 5.54 mmol) according to the gen-
eral procedure for synthesis of compounds 6aed; pale yellow
crystals, yield 865 mg (50%); mp 172e175 C; [a]D ¼ 80.4 (c ¼ 0.5,
CDCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 4.33 (dd, J ¼ 11.7,
7.3 Hz, 1H, 3-CH2), 4.38 (dd, J ¼ 11.1, 5.6 Hz, 1H, CH2O), 4.45 (dd,
J ¼ 11.1, 3.7 Hz, 1H, CH2O), 4.62 (dd, J ¼ 11.7, 2.5 Hz, 1H, 3-CH2),
4.72e4.78 (m, 1H, 2-CH), 7.11e7.23 (m, 3H, AreH8, AreH2’, AreH6’),
7.76e7.84 (m, 4H, AreH5, AreH7, AreH3’, AreH5’); 13C NMR
(101 MHz, DMSO-d6): d (ppm) 65.0 (C-3), 66.5 (CH2O), 71.4 (C-2),
103.4 (C-40), 112.7 (C-7), 115.7 (C-20, C-60), 117.5, 117.6 (C-5, C-8),
119.0 (CN), 134.2 (C-30, C-50), 141.2 (C-6), 142.4, 149.0 (C-4a, C-8a),
161.4 (C-10); HRMS (ESI) m/z calcd for C16H13N2O5 [M þ H]þ
313.0824, found 313.0813; IR (KBr, v, cm1): 2227, 1603, 1514, 1349,
1256, 1174, 839; HPLC: 100%, tr 16.0 min; Anal. (C16H12N2O5) C, H, N.
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benzonitrile (6c)
Synthesized from 5c (1.17 g, 5.54mmol) according to the general
procedure for synthesis of compounds 6aed; pale yellow crystals,
yield 865 mg (50%); mp 159e162 C; [a]D ¼ 29.7 (c ¼ 0.5, CDCl3);
1H NMR (400 MHz, DMSO-d6): d (ppm) 4.33 (dd, J¼ 11.7, 7.3 Hz, 1H,
3-CH2), 4.38 (dd, J¼ 11.2, 5.7 Hz,1H, CH2O), 4.45 (dd, J¼ 11.2, 3.7 Hz,
1H, CH2O), 4.62 (dd, J¼ 11.7, 2.5 Hz,1H, 3-CH2), 4.71e4.79 (m,1H, 2-
CH), 7.14e7.21 (m, 3H, AreH5, AreH2’, AreH6’), 7.75e7.85 (m, 4H,
AreH6, AreH8, AreH3’, AreH5’); 13C NMR (101 MHz, DMSO-d6):
d (ppm) 65.0 (C-3), 66.5 (CH2O), 71.4 (C-2), 103.4 (C-40), 112.7 (C-6),
115.7 (C-20, C-60), 117.5, 117.6 (C-5, C-8), 119.0 (CN), 134.2 (C-30, C-50),
141.2 (C-7), 142.5, 149.0 (C-4a, C-8a), 161.4 (C-10); HRMS (ESI) m/z
calcd for C16H13N2O5 [Mþ H]þ 313.0824, found 313.0827; IR (KBr, v,
cm1): 2227, 1605, 1515, 1457, 1350, 1256, 1175, 839; HPLC: 100%, tr
16.0 min; Anal. (C16H12N2O5) C, H, N.
6.11. (S)-4-((7-nitro-2,3-dihydro-1,4-benzodioxin-2-yl)methoxy)
benzonitrile (6d)
Synthesized from 5d (1.17 g, 5.54 mmol) according to the
general procedure for synthesis of compounds 6aed; pale yellow
crystals, yield 830 mg (48%); mp 168e171 C; [a]D ¼þ30.2 (c¼ 0.5,
CHCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 4.33 (dd, J ¼ 11.7,
7.3 Hz, 1H, 3-CH2), 4.38 (dd, J ¼ 11.1, 5.7 Hz, 1H, CH2O), 4.45 (dd,
J ¼ 11.1, 3.7 Hz, 1H, CH2O), 4.62 (dd, J ¼ 11.7, 2.5 Hz, 1H, 3-CH2),
4.68e4.81 (m, 1H, 2-CH), 7.11e7.23 (m, 3H, AreH5, AreH2’, AreH6’),
7.74e7.85 (m, 4H, AreH6, AreH8, AreH3’, AreH5’); 13C NMR
(101 MHz, DMSO-d6): d (ppm) 64.9 (C-3), 66.5 (CH2O), 71.4 (C-2),
103.4 (C-40), 112.7 (C-6), 115.7 (C-20, C-60), 117.5, 117.6 (C-5, C-
8), 119.0 (CN), 134.2 (C-30, C-50), 141.2 (C-7), 142.5, 149.0 (C-4a, C-
8a), 161.4 (C-10); HRMS (ESI) m/z calcd for C16H13N2O5 [M þ H]þ
313.0824, found 313.0833; IR (KBr, v, cm1): 2225, 1600,
1504, 1349, 1251, 820; HPLC: 100%, tr 16.0 min; Anal. (C16H12N2O5)
C, H, N.
6.12. (R)-4-((6-(benzylamino)-2,3-dihydro-1,4-benzodioxin-2-yl)
methoxy)benzonitrile (8a). General procedure for synthesis of
compounds 8aed
To a solution of compound 6a (800 mg, 2.56 mmol) in 100 mL
MeOH, 10% Pd/C (80 mg) was added and the mixture was stirred in
a hydrogenator at 25 bar for 1 h till the reactionwas completed. The
catalyst was ﬁltered off and the solvent was evaporated in vacuo to
yield 720 mg (100%) of 7awhich was used in the next step without
puriﬁcation. To a solution of the crude amine 7a (722 mg,
2.56mmol) in methanol (50mL) containingmolecular sieves under
argon atmosphere, benzaldehyde (406 mg, 3.83 mmol) was added
and the mixture was stirred at room temperature for 12 h, until the
aldimine formation was completed. The reaction mixture contain-
ing aldimine in methanol was carefully treated with NaBH4
(154 mg, 4.08 mmol) and stirred for additional 1 h, ﬁltered, and the
solvent was evaporated in vacuo. The crude residue was dissolved
in dichloromethane (50 mL) and washed successively with satu-
rated NaHCO3 solution (3  50 mL) and brine (1  50 mL). The
organic phase was dried over Na2SO4 and the solvent evaporated
under reduced pressure. The oily product was puriﬁed by column
chromatography using dichloromethane as eluant to obtain 439mg
(46%) of 8a as yellow crystals; mp 144e147 C; [a]D ¼ þ32.4
(c ¼ 0.5, CHCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 4.05 (dd,
J ¼ 11.4, 7.9 Hz, 1H, 3-CH2), 4.18 (s, 2H, NCH2), 4.22e4.36 (m, 3H, 3-
CH2, CH2O), 4.38e4.47 (m, 1H, 2-CH), 5.92 (bs, 1H, NH), 6.09 (d,
J ¼ 2.6 Hz, 1H, AreH5), 6.15 (dd, J ¼ 8.7, 2.6 Hz, 1H, AreH7), 6.62 (d,
J¼ 8.7 Hz, 1H, AreH8), 7.16 (d, J¼ 9.0 Hz, 2H, AreH2’, AreH6’), 7.19e7.25 (m, 1H, Ph), 7.27e7.39 (m, 4H, Ph), 7.78 (d, J ¼ 9.0 Hz, 2H, Are
H3’, AreH5’); 13C NMR (101MHz, DMSO-d6): d (ppm) 47.0 (PheCH2),
64.7 (C-3), 66.9 (CH2O), 70.7 (C-2), 100.4 (C-5), 103.2 (C-40), 106.5
(C-7), 115.6 (C-20, C-60), 117.2 (C-8), 119.0 (CN), 126.5 (C-400), 127.1 (C-
200, C-600), 128.2 (C-300, C-500), 133.3 (C-8a), 134.2 (C-30, C-50), 140.4 (C-
6), 143.0 (C-100), 143.7 (C-4a), 161.6 (C-10); HRMS (ESI) m/z calcd for
C23H21N2O3 [M þ H]þ 373. 1552, found 373.1547; IR (KBr, v, cm1):
3378, 2221, 1508, 1250, 1176, 828; HPLC: 100%, tr 11.7 min; Anal.
(C23H20N2O3) C, H, N.
6.13. (S)-4-((6-(benzylamino)-2,3-dihydro-1,4-benzodioxin-2-yl)
methoxy)benzonitrile (8b)
Synthesized from 6b (800 mg, 2.56 mmol) according to the
general procedure for synthesis of compounds 8aed; yellow
crystals, yield 439 mg (46%); mp 88e91 C; [a]D ¼ 32.8 (c ¼ 0.5
in CHCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 4.00
(dd, J ¼ 11.4, 7.2 Hz, 1H, 3-CH2), 4.18 (d, J ¼ 5.9 Hz, 2H, NCH2),
4.23e4.35 (m, 3H, 3-CH2, CH2O), 4.44e4.55 (m, 1H, 2-CH), 5.93 (bt,
J ¼ 6.1 Hz, 1H, NH), 6.07 (d, J ¼ 2.6 Hz, 1H, AreH5), 6.15 (dd, J ¼ 8.7,
2.7 Hz, 1H, AreH7), 6.62 (d, J ¼ 8.7 Hz, 1H, AreH8), 7.16 (d,
J ¼ 9.0 Hz, 2H, AreH2’, AreH6’), 7.19e7.26 (m, 1H, Ph), 7.28e7.37
(m, 4H, Ph), 7.78 (d, J ¼ 9.0 Hz, 2H, AreH3’, AreH5’); 13C NMR
(101 MHz, DMSO-d6): d (ppm) 47.0 (PheCH2), 64.2 (C-3), 66.9
(CH2O), 71.4 (C-2), 100.3 (C-5), 103.2 (C-40), 106.3 (C-7), 115.6 (C-20,
C-60), 117.1 (C-8), 119.0 (CN), 126.4 (C-400), 127.1 (C-200, C-600), 128.2
(C-300, C-500), 133.6 (C-8a), 134.2 (C-30, C-50), 140.4 (C-6), 142.7 (C-
100), 143.9 (C-4a), 161.6 (C-10); HRMS (ESI)m/z calcd for C23H21N2O3
[M þ H]þ 373.1552, found 373.1534; IR (KBr, v, cm1): 2219, 1606,
1504, 1260, 1174, 1045, 830; HPLC: 98.1%, tr 11.7 min; Anal.
(C23H20N2O3) C, H, N.
6.14. (R)-4-((7-(benzylamino)-2,3-dihydro-1,4-benzodioxin-2-yl)
methoxy)benzonitrile (8c)
Synthesized from 6c (800 mg, 2.56 mmol) according to the
general procedure for synthesis of compounds 8aed; yellow
crystals, yield 420 mg (44%); mp 111e114 C; [a]D ¼ 42.5
(c ¼ 0.8, CDCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 4.00
(dd, J ¼ 11.5, 7.2 Hz, 1H, 3-CH2), 4.18 (d, J ¼ 4.8 Hz, 2H, NCH2),
4.22e4.35 (m, 3H, 3-CH2, CH2O), 4.43e4.57 (m, 1H, 2-CH), 5.93
(bt, J ¼ 5.6 Hz, 1H, NH), 6.07 (d, J ¼ 2.6 Hz, 1H, AreH8), 6.15 (dd,
J ¼ 8.7, 2.6 Hz, 1H, AreH6), 6.62 (d, J ¼ 8.7 Hz, 1H, AreH5), 7.16 (d,
J ¼ 9.0 Hz, 2H, AreH2’, AreH6’), 7.19e7.25 (m, 1H, Ph), 7.27e7.38
(m, 4H, Ph), 7.78 (d, J ¼ 9.0 Hz, 2H, AreH3’, AreH5’); 13C NMR
(101 MHz, DMSO-d6): d (ppm) 47.0 (PheCH2) 64.2 (C-3), 66.7
(CH2O), 71.4 (C-2), 100.3 (C-8), 103.2 (C-40), 106.3 (C-6), 115.6 (C-20,
C-60), 117.1 (C-5), 119.0 (CN), 126.5 (C-400), 127.1 (C-200, C-600), 128.2
(C-300, C-500), 133.6 (C-8a), 134.2 (C-30, C-50), 140.4 (C-7), 142.7 (C-
100), 143.9 (C-4a), 161.6 (C-10); HRMS (ESI) m/z calcd for
C23H21N2O3 [M þ H]þ 373. 1552, found 373.1545; IR (KBr, v, cm1):
3387, 3050, 2220, 1508, 1262, 1174, 832; HPLC: 98.8%, tr 11.7 min;
Anal. (C23H20N2O3) C, H, N.
6.15. (S)-4-((7-(benzylamino)-2,3-dihydro-1,4-benzodioxin-2-yl)
methoxy)benzonitrile (8d)
Synthesized from 7d (800 mg, 2.56 mmol) according to the
general procedure for synthesis of compounds 8aed; yellow
crystals, yield 430 mg (45%); mp 86e89 C; [a]D ¼ þ44.4 (c ¼ 0.8,
CDCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 4.00 (dd, J ¼ 11.4,
7.2 Hz, 1H, 3-CH2), 4.18 (d, J ¼ 5.7 Hz, 2H, NCH2), 4.24e4.34 (m, 3H,
3-CH2, CH2O), 4.46e4.53 (m, 1H, 2-CH), 5.93 (bt, J ¼ 5.9 Hz, 1H,
NH), 6.07 (d, J ¼ 2.6 Hz, 1H, AreH8), 6.15 (dd, J ¼ 8.7, 2.6 Hz,
1H, AreH6), 6.62 (d, J ¼ 8.7 Hz, 1H, AreH5), 7.16 (d, J ¼ 8.9 Hz, 2H,
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(d, J ¼ 8.9 Hz, 2H, AreH3’, AreH5’); 13C NMR (101 MHz, DMSO-d6):
d (ppm) 47.0 (PheCH2), 64.2 (C-3), 66.9 (CH2O), 71.4 (C-2), 100.3
(C-8), 103.2 (C-40), 106.3 (C-6), 115.6 (C-20, C-60), 117.1 (C-5), 119.0
(CN), 126.4 (C-400), 127.1 (C-200, C-600), 128.2 (C-300, C-500), 133.6 (C-
8a), 134.2 (C-30, C-50), 140.4 (C-7), 142.7 (C-100), 143.9 (C-4a), 161.6
(C-10); HRMS (ESI) m/z calcd for C23H21N2O3 [M þ H]þ
373.1552, found 373.1548; IR (KBr, v, cm1): 3386, 3059, 2220,
1606, 1509, 1262, 1174, 832; HPLC: 93.6%, tr 11.8 min; Anal.
(C23H20N2O3) C, H, N.
6.16. (R)-ethyl 2-(benzyl(2-((4-cyanophenoxy)methyl)-2,3-dihydro-
1,4-benzodioxin-6-yl)amino)-2-oxoacetate (9a). General procedure
for the synthesis of compounds 9aed
Ethyl oxalyl chloride (185 mg, 1.35 mmol) was added to a solu-
tion of 8a (420 mg, 1.13 mmol) and triethylamine (136 mg,
1.35 mmol) in dichloromethane (50 mL) and the mixture was
stirred for 2 h. The solvent was removed under reduced pressure,
the residue dissolved in ethyl acetate (50 mL) and washed suc-
cessively with a 10% citric acid solution (3  50 mL), saturated
NaHCO3 solution (3  50 mL) and brine (1  50 mL). The organic
phase was dried over Na2SO4 and the solvent evaporated under
reduced pressure. The oily product was puriﬁed by column chro-
matography on silica gel using dichloromethane as eluant to obtain
497mg (93%) of 9a as pale yellow solid; mp 42e45 C; [a]D¼þ28.4
(c ¼ 0.5, CHCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 0.93 (t,
J ¼ 7.1 Hz, 3H, CH2CH3), 4.02 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 4.13 (dd,
J¼ 11.6, 7.4 Hz, 1H, 3-CH2), 4.30 (dd, J¼ 11.0, 5.7 Hz, 1H, CH2O), 4.37
(dd, J¼ 11.0, 3.7 Hz, 1H, CH2O), 4.44 (dd, J ¼ 11.6, 2.4 Hz, 1H, 3-CH2),
4.56e4.64 (m,1H, 2-CH), 4.90 (s, 2H, NCH2), 6.62 (dd, J¼ 8.6, 2.7 Hz,
1H, AreH7), 6.78 (d, J ¼ 2.7 Hz, 1H, AreH5), 6.89 (d, J ¼ 8.6 Hz, 1H,
AreH8), 7.15 (d, J ¼ 9.0 Hz, 2H, AreH2’, AreH6’), 7.18e7.22 (m, 2H,
Ph), 7.27e7.37 (m, 3H, Ph), 7.79 (d, J ¼ 9.0 Hz, 2H, AreH3’, AreH5’);
13C NMR (101 MHz, DMSO-d6): d (ppm) 13.4 (CH2eCH3), 50.8 (Phe
CH2), 61.3 (CH2eCH3), 64.4 (C-3), 66.6 (CH2O), 71.3 (C-2), 103.3 (C-
40), 115.6 (C-20, C-60), 116.2 (C-7), 117.4 (C-5), 119.0 (CN), 120.9 (C-8),
127.5 (C-400), 128.0 (C-200, C-600), 128.6 (C-300, C-500), 132.3 (C-6), 134.2
(C-30, C-50), 136.1 (C-100), 142.6, 142.7 (C-4a, C-8a), 161.4, 161.5, 162.4
(COeCOO, COeCOO, C-10); HRMS (ESI) m/z calcd for C27H25N2O6
[M þ H]þ 473.1713, found 473.1706; IR (KBr, v, cm1): 2224, 1605,
1507, 1252, 1175, 1016, 834; HPLC: 100%, tr 17.6 min; Anal.
(C27H24N2O6) C, H, N.
6.17. (S)-ethyl 2-(benzyl(2-((4-cyanophenoxy)methyl)-2,3-dihydro-
1,4-benzodioxin-6-yl)amino)-2-oxoacetate (9b)
Synthesized from 8b (420 mg, 1.13 mmol) according to the
general procedure for the synthesis of compounds 9aed; pale
yellow solid, yield 481 mg (90%); mp 41e44 C; [a]D ¼ 27.8
(c ¼ 0.5, CHCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 0.90 (t,
J ¼ 7.1 Hz, 3H, CH2CH3), 4.00 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 4.14 (dd,
J¼ 11.6, 7.3 Hz, 1H, 3-CH2), 4.29 (dd, J¼ 11.0, 5.9 Hz, 1H, CH2O), 4.37
(dd, J¼ 11.0, 3.5 Hz, 1H, CH2O), 4.44 (dd, J ¼ 11.6, 2.4 Hz, 1H, 3-CH2),
4.56e4.63 (m,1H, 2-CH), 4.90 (s, 2H, NCH2), 6.62 (dd, J¼ 8.6, 2.5 Hz,
1H, AreH7), 6.80 (d, J ¼ 2.5 Hz, 1H, AreH5), 6.88 (d, J ¼ 8.6 Hz, 1H,
AreH8), 7.16 (d, J ¼ 9.0 Hz, 2H, AreH2’, AreH6’), 7.17e7.21 (m, 2H,
Ph), 7.23e7.36 (m, 3H, Ph), 7.79 (d, J ¼ 8.9 Hz, 2H, AreH3’, AreH5’);
13C NMR (101 MHz, DMSO-d6): d (ppm) 13.3 (CH2eCH3), 50.8 (Phe
CH2), 61.3 (CH2eCH3), 64.4 (C-3), 66.6 (CH2O), 71.3 (C-2), 103.3 (C-
40), 115.6 (C-20, C-60), 116.2 (C-7), 117.2 (C-5), 119.0 (CN), 120.7 (C-8),
127.5 (C-400), 127.9 (C-200, C-600), 128.6 (C-300, C-500), 132.5 (C-6), 134.2
(C-30, C-50), 136.1 (C-100), 142.5, 142.8 (C-4a, C-8a), 161.4, 161.5, 162.4
(COeCOO, COeCOO, C-10); HRMS (ESI) m/z calcd for C27H25N2O6
[M þ H]þ 473.1713, found 473.1732; IR (KBr, v, cm1): 2225, 1741,1669, 1606, 1507, 1256, 1172, 1028, 835; HPLC: 100%, tr 17.6 min;
Anal. (C27H24N2O6) C, H, N.
6.18. (R)-ethyl 2-(benzyl(3-((4-cyanophenoxy)methyl)-2,3-dihydro-
1,4-benzodioxin-7-yl)amino)-2-oxoacetate (9c)
Synthesized from 8c (420 mg, 1.13 mmol) according to the
general procedure for the synthesis of compounds 9aed; pale
yellow solid, yield 486 mg (91%); mp 43e46 C; [a]D ¼ 14.2
(c ¼ 0.5, CHCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 0.90 (t,
J ¼ 7.1 Hz, 3H, CH2CH3), 4.00 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 4.14 (dd,
J¼ 11.6, 7.3 Hz, 1H, 3-CH2), 4.29 (dd, J¼ 11.0, 5.8 Hz, 1H, CH2O), 4.37
(dd, J ¼ 11.0, 3.6 Hz, 1H, CH2O), 4.44 (dd, J¼ 11.6, 2.4 Hz, 1H, 3-CH2),
4.55e4.64 (m,1H, 2-CH), 4.90 (s, 2H, NCH2), 6.62 (dd, J¼ 8.6, 2.6 Hz,
1H, AreH6), 6.80 (d, J ¼ 2.6 Hz, 1H, AreH8), 6.88 (d, J ¼ 8.6 Hz, 1H,
AreH5), 7.16 (d, J ¼ 9.0 Hz, 2H, AreH2’, AreH6’), 7.17e7.21 (m, 2H,
Ph), 7.25e7.35 (m, 3H, Ph), 7.80 (d, J ¼ 9.0 Hz, 2H, AreH3’, AreH5’);
13C NMR (101 MHz, DMSO-d6): d (ppm) 13.3 (CH2eCH3), 50.8 (Phe
CH2), 61.3 (CH2eCH3), 64.4 (C-3), 66.6 (CH2O), 71.3 (C-2), 103.3 (C-
40), 115.6 (C-20, C-60), 116.2 (C-6), 117.2 (C-5), 119.0 (CN), 120.7 (C-8),
127.5 (C-400), 127.9 (C-200, C-600), 128.6 (C-300, C-500), 132.5 (C-7), 134.2
(C-30, C-50), 136.1 (C-100), 142.5, 142.8 (C-4a, C-8a), 161.4, 161.5, 162.4
(COeCOO, COeCOO, C-10); HRMS (EI) m/z calcd for C27H25N2O6
[M þ H]þ 473.1713, found 473.1718; IR (KBr, v, cm1): 2224, 1741,
1669, 1605, 1508, 1257, 1173, 1028, 834; HPLC: 100%, tr 17.5 min;
Anal. (C27H24N2O6) C, H, N.
6.19. (S)-ethyl 2-(benzyl(3-((4-cyanophenoxy)methyl)-2,3-dihydro-
1,4-benzodioxin-7-yl)amino)-2-oxoacetate (9d)
Synthesized from 8d (420 mg, 1.13 mmol) according to the
general procedure for the synthesis of compounds 9aed; pale
yellow solid, yield 470 mg (88%); mp 45e48 C; [a]D ¼ þ12.8
(c ¼ 0.5, CHCl3); 1H NMR (400 MHz, DMSO-d6): d (ppm) 0.93 (t,
J ¼ 7.1 Hz, 3H, CH2CH3), 4.02 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 4.13 (dd,
J¼ 11.6, 7.4 Hz, 1H, 3-CH2), 4.30 (dd, J¼ 11.0, 5.8 Hz, 1H, CH2O), 4.37
(dd, J ¼ 11.0, 3.7 Hz, 1H, CH2O), 4.44 (dd, J¼ 11.6, 2.4 Hz, 1H, 3-CH2),
4.56e4.64 (m,1H, 2-CH), 4.90 (s, 2H, NCH2), 6.62 (dd, J¼ 8.6, 2.5 Hz,
1H, AreH6), 6.78 (d, J ¼ 2.5 Hz, 1H, AreH8), 6.89 (d, J ¼ 8.6 Hz, 1H,
AreH5), 7.15 (d, J ¼ 9.0 Hz, 2H, AreH2’, AreH6’), 7.17e7.22 (m, 2H,
Ph), 7.25e7.38 (m, 3H, Ph), 7.79 (d, J ¼ 9.0 Hz, 2H, AreH3’, AreH5’);
13C NMR (101 MHz, DMSO-d6): d (ppm) 13.4 (CH2eCH3), 50.8 (Phe
CH2), 61.3 (CH2eCH3), 64.4 (C-3), 66.6 (CH2O), 71.3 (C-2), 103.3 (C-
40), 115.6 (C-20, C-60), 116.1 (C-6), 117.4 (C-5), 119.0 (CN), 120.9 (C-8),
127.5 (C-400), 128.0 (C-200, C-600), 128.6 (C-300, C-500), 132.3 (C-7), 134.2
(C-30, C-50), 136.1 (C-100), 142.6, 142.7 (C-4a, C-8a), 161.4, 161.5, 162.4
(COeCOO, COeCOO, C-10); HRMS (ESI) m/z calcd for C27H25N2O6
[M þ H]þ 473.1713, found 473.1704; IR (KBr, v, cm1): 2225, 1741,
1670, 1606, 1508, 1256, 1172, 1029, 835; HPLC: 100%, tr 17.5 min;
Anal. (C27H24N2O6  1/2H2O) C, H, N.
6.20. (R)-ethyl 2-(benzyl(2-((4-carbamimidoylphenoxy)methyl)-2,3-
dihydro-1,4-benzodioxin-6-yl)amino)-2-oxoacetate triﬂuoroacetate
(10a). General procedure for synthesis of amidines 10aed
Gaseous HCl was slowly introduced over 30 min into a solution
of the nitrile 9a (480 mg, 1.02 mmol) in anhydrous ethanol (30 mL).
The reaction mixturewas closed tightly and stirred for 24 h at room
temperature. The solvent was evaporated in vacuo and the residue
washed 3 times with anhydrous diethyl ether. Obtained iminoether
was dissolved in anhydrous EtOH (30 mL), ammonium acetate (3
eq, 237 mg, 3.06 mmol) was added and the reactionmixture stirred
for 24 h at room temperature. The solvent was evaporated and
crude product was puriﬁed by reverse phase column chromatog-
raphy with gradient using methanol/triﬂuoroacetic acid (40e80%
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were precipitated from triﬂuoroacetic acid, ﬁltered off and dried to
yield 350 mg (70%) of 10a as a white powder; yield 350 mg (58%);
mp 188e191 C; [a]D ¼ þ31.4 (c ¼ 0.5, EtOH); 1H NMR (400 MHz,
DMSO-d6): d (ppm) 0.93 (t, J ¼ 7.1 Hz, 3H, CH2CH3), 4.02 (q,
J ¼ 7.1 Hz, 2H, CH2CH3), 4.14 (dd, J ¼ 11.6, 7.4 Hz, 1H, 3-CH2), 4.32
(dd, J ¼ 11.0, 5.8 Hz, 1H, CH2O), 4.39 (dd, J ¼ 11.0, 3.7 Hz, 1H, CH2O),
4.46 (dd, J ¼ 11.6, 2.4 Hz, 1H, 3-CH2), 4.57e4.65 (m, 1H, 2-CH), 4.90
(s, 2H, NCH2), 6.63 (dd, J ¼ 8.6, 2.6 Hz, 1H, AreH7), 6.79 (d,
J ¼ 2.6 Hz, 1H, AreH6), 6.89 (d, J¼ 8.6 Hz, 1H, AreH8), 7.17e7.24 (m,
4H, Ph, AreH2’, AreH6’), 7.25e7.38 (m, 3H, Ph), 7.83 (d, J ¼ 9.0 Hz,
2H, AreH3’, AreH5’), 8.92 (bs, 2H, NH2), 9.16 (bs, 2H, NH2þ); 13C NMR
(101 MHz, DMSO-d6): d (ppm) 13.4 (CH2eCH3), 50.8 (PheCH2), 61.3
(CH2eCH3), 64.4 (C-3), 66.7 (CH2O), 71.3 (C-2), 114.8 (C-20, C-60),
116.2 (C-7), 117.4 (C-5), 120.1 (C-40), 120.9 (C-8), 127.6 (C-400), 128.0
(C-200, C-600), 128.6 (C-300, C-500), 130.2 (C-30, C-50), 132.3 (C-6), 136.1
(C-100), 142.6, 142.7 (C-4a, C-8a), 161.5, 162.3, 162.4, 164.5 (COeCOO,
COeCOO, C-10, C(]NH)NH2), 117,1 (CF3eCOOH, 1JC,F ¼ 299,3 Hz),
158,7 (CF3eCOOH, 2JC,F ¼ 31,5 Hz); HRMS (ESI) m/z calcd for
C27H28N3O6 [M þ H]þ 490.1978, found 490.1967; IR (KBr, v, cm1):
3299, 3116, 1737, 1667, 1506, 1203, 844; HPLC: 99.0%, tr 12.5 min;
Anal. (C27H27N3O6  CF3COOH) C, H, N.
6.21. (S)-ethyl 2-(benzyl(2-((4-carbamimidoylphenoxy)methyl)-2,3-
dihydro-1,4-benzodioxin-6-yl)amino)-2-oxoacetate triﬂuoroacetate
(10b)
Synthesized from 9b (480 mg, 1.02 mmol) according to the
general procedure for synthesis of amidines 10aed; white powder,
yield 325mg (53%); mp 190e193 C; [a]D¼32.0 (c¼ 0.5 in EtOH);
1H NMR (400 MHz, DMSO-d6): d (ppm) 0.93 (t, J ¼ 7.1 Hz, 3H,
CH2CH3), 4.02 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 4.14 (dd, J ¼ 11.6, 7.4 Hz,
1H, 3-CH2), 4.32 (dd, J ¼ 11.0, 5.7 Hz, 1H, CH2O), 4.39 (dd, J ¼ 11.0,
3.6 Hz, 1H, CH2O), 4.46 (dd, J ¼ 11.6, 2.4 Hz, 1H, 3-CH2), 4.57e4.66
(m, 1H, 2-CH), 4.91 (s, 2H, NCH2), 6.63 (dd, J ¼ 8.6, 2.7 Hz, 1H,
AreH7), 6.79 (d, J ¼ 2.7 Hz, 1H, AreH5), 6.89 (d, J ¼ 8.6 Hz, 1H, Are
H8), 7.16e7.25 (m, 4H, Ph, AreH2’, AreH6’), 7.27e7.37 (m, 3H, Ph),
7.83 (d, J ¼ 9.0 Hz, 2H, AreH3’, AreH5’), 8.92 (bs, 2H, NH2), 9.16 (bs,
2H, NH2þ); 13C NMR (101 MHz, DMSO-d6): d (ppm) 13.4 (CH2eCH3),
50.8 (PheCH2), 61.3 (CH2eCH3), 64.4 (C-3), 66.7 (CH2O), 71.3 (C-2),
114.8 (C-20, C-60), 116.2 (C-7), 117.4 (C-5), 120.1 (C-40), 120.9 (C-8),
127.6 (C-400), 128.0 (C-200, C-600), 128.6 (C-300, C-500), 130.2 (C-30, C-50),
132.3 (C-6), 136.1 (C-100), 142.6, 142.7 (C-4a, C-8a), 161.5,
162.3, 162.4, 164.5 (COeCOO, COeCOO, C-10, C(]NH)NH2), 117.1
(CF3eCOOH, 1JC,F ¼ 299.2 Hz), 158.8 (CF3eCOOH, 2JC,F ¼ 31.5 Hz);
HRMS (ESI) m/z calcd for C27H28N3O6 [M þ H]þ 490.1978, found
490.1963; IR (KBr, v, cm1): 3298, 3122, 1737, 1665, 1506, 1203, 843;
HPLC: 100%, tr 12.4 min; Anal. (C27H27N3O6  CF3COOH  1/9H2O)
C, H, N.
6.22. (R)-ethyl 2-(benzyl(3-((4-carbamimidoylphenoxy)methyl)-2,3-
dihydro-1,4-benzodioxin-7-yl)amino)-2-oxoacetate triluoroacetate
(10c)
Synthesized from 9c (480 mg, 1.02 mmol) according to the
general procedure for synthesis of amidines 10aed; white powder,
yield 335 mg (54%); mp 185e188 C; [a]D ¼ þ11.8 (c ¼ 2.0, DMSO);
1H NMR (400 MHz, DMSO-d6): d (ppm) 0.91 (t, J ¼ 7.0 Hz, 3H,
CH2CH3), 4.00 (q, J ¼ 7.0 Hz, 2H, CH2CH3), 4.15 (dd, J ¼ 11.6, 7.2 Hz,
1H, 3-CH2), 4.31 (dd, J ¼ 11.0, 6.0 Hz, 1H, CH2O), 4.39 (dd, J ¼ 11.0,
3.4 Hz, 1H, CH2O), 4.46 (dd, J ¼ 11.6, 2.2 Hz, 1H, 3-CH2), 4.58e4.64
(m, 1H, 2-CH), 4.90 (s, 2H, NCH2), 6.63 (dd, J ¼ 8.7, 2.5 Hz, 1H, Are
H6), 6.80 (d, J ¼ 2.5 Hz, 1H, AreH8), 6.89 (d, J ¼ 8.7 Hz, 1H, AreH5),
7.15e7.38 (m, 7H, Ph, AreH2’, AreH6’), 7.83 (d, J ¼ 8.9 Hz, 2H, Are
H3’, AreH5’), 8.91 (bs, 2H, NH2), 9.17 (bs, 2H, NH2þ); 13C NMR(101 MHZ, DMSO-d6): d (ppm) 13.3 (CH2eCH3), 50.8 (PheCH2), 61.3
(CH2eCH3), 64.4 (C-3), 66.7 (CH2O), 71.3 (C-2), 114.8 (C-20, C-60),
116.2 (C-6), 117.3 (C-5), 120.1 (C-40), 120.8 (C-8), 127.5 (C-400), 127.9
(C-200, C-600), 128.6 (C-300, C-500), 130.2 (C-30, C-50), 132.5 (C-7), 136.1
(C-100), 142.5, 142.8 (C-4a, C-8a), 161.5, 162.3, 162.4, 164.5 (COeCOO,
COeCOO, C-10, C(]NH)NH2), 117.1 (CF3eCOOH, 1JC,F ¼ 299.2 Hz),
158.8 (CF3eCOOH, 2JC,F ¼ 31.5 Hz); HRMS (ESI) m/z calcd for
C27H28N3O6 [M þ H]þ 490.1978, found 490.1996; IR (KBr, v, cm1):
3345, 3109, 1742, 1670, 1500, 1197, 843; HPLC: 98.4%, tr 12.7 min;
Anal. (C27H27N3O6  CF3COOH) C, H, N.6.23. (S)-ethyl 2-(benzyl(3-((4-carbamimidoylphenoxy)methyl)-
2,3-dihydro-1,4-benzodioxin-7-yl)amino)-2-oxoacetate (10d)
Synthesized from 9d (480 mg, 1.02 mmol) according to the
general procedure for synthesis of amidines 10aed; white pow-
der, yield 345 mg (56%); mp 188e191 C; [a]D ¼ 12.8 (c ¼ 2.0,
DMSO); 1H NMR (400 MHz, DMSO-d6): d (ppm) 0.91 (t, J ¼ 7.1 Hz,
3H, CH2CH3), 4.00 (q, J ¼ 7.1 Hz, 2H, CH2CH3), 4.15 (dd, J ¼ 11.6,
7.3 Hz, 1H, 3-CH2), 4.31 (dd, J ¼ 11.0, 5.9 Hz, 1H, CH2O), 4.39 (dd,
J ¼ 11.0, 3.5 Hz, 1H, CH2O), 4.46 (dd, J ¼ 11.6, 2.2 Hz, 1H, 3-CH2),
4.53e4.68 (m, 1H, 2-CH), 4.90 (s, 2H, NCH2), 6.63 (dd, J ¼ 8.6,
2.5 Hz, 1H, AreH6), 6.80 (d, J ¼ 2.5 Hz, 1H, AreH8), 6.89 (d,
J¼ 8.6 Hz,1H, AreH5), 7.17e7.24 (m, 4H, Ph, AreH2’, AreH6’), 7.26e
7.37 (m, 3H, Ph), 7.83 (d, J ¼ 8.9 Hz, 2H, AreH3’, AreH5’), 8.93 (bs,
2H, NH2), 9.17 (bs, 2H, NH2þ); 13C NMR (101 MHz, DMSO-d6):
d (ppm) 13.3 (CH2eCH3), 50.8 (PheCH2), 61.3 (CH2eCH3), 64.4 (C-
3), 66.7 (CH2O), 71.3 (C-2), 114.8 (C-20, C-60), 116.2 (C-6), 117.3 (C-
5), 120.1 (C-40), 120.8 (C-8), 127.5 (C-400), 127.9 (C-200, C-600), 128.6
(C-300, C-500), 130.2 (C-30, C-50), 132.5 (C-7), 136.1 (C-100), 142.5,
142.8 (C-4a, C-8a), 161.5, 162.3, 162.4, 164.5 (COeCOO, COeCOO, C-
10, C(]NH)NH2); HRMS (ESI) m/z calcd for C27H28N3O6 [M þ H]þ
490.1978, found 490.1987; IR (KBr, v, cm1): 3342, 3110, 1742,
1670, 1499, 1196, 844; HPLC: 98.4%, tr 12.7 min; Anal.
(C27H27N3O6  CF3COOH) C, H, N.6.24. (R)-2-(benzyl(2-((4-carbamimidoylphenoxy)methyl)-2,3-
dihydro-1,4-benzodioxin-6-yl)amino)-2-oxoacetic acid (11a).
General procedure for synthesis of compounds 11aed
To a solution of 10a (150 mg, 0.31 mmol) in a mixture of
tetrahydrofuran (3 mL) and methanol (1 mL), 1 M LiOH (1.50 mL,
1.50 mmol) was added and the reaction mixture stirred at room
temperature for 1 h. The solvents was evaporated in vacuum and
the resulting aqueous solution neutralized with 0.1% triﬂuoro-
acetic acid until the product started to precipitate (pH ¼ 2). The
product was ﬁltered off and dried to obtain 79 mg (68%) of 11a as
a white powder; mp 290e293 C; [a]D ¼ þ59.6 (c ¼ 2.0, DMSO);
1H NMR (400 MHz, DMSO-d6): d (ppm) 4.14 (dd, J ¼ 11.6, 7.6 Hz,
1H, 3-CH2), 4.33 (dd, J ¼ 11.0, 5.6 Hz, 1H, CH2O), 4.40 (dd, J ¼ 11.0,
3.7 Hz, 1H, CH2O), 4.46 (dd, J ¼ 11.6, 2.3 Hz, 1H, 3-CH2), 4.57e4.66
(m, 1H, 2-CH), 4.88 (s, 2H, NCH2), 6.67 (dd, J ¼ 8.6, 2.5 Hz, 1H, Are
H7), 6.80 (d, J ¼ 2.5 Hz, 1H, AreH5), 6.89 (d, J ¼ 8.6 Hz, 1H, Are
H8), 7.18e7.24 (m, 4H, Ph, AreH2’, AreH6’), 7.27e7.35 (m, 3H,
Ph), 7.83 (d, J ¼ 8.9 Hz, 2H, AreH3’, AreH5’), 9.04 (bs, 2H, NH2),
9.17 (bs, 1H, NH); 13C NMR (101 MHz, DMSO-d6): d (ppm) 49.6
(PheCH2), 64.4 (C-3), 66.7 (CH2O), 71.0 (C-2), 114.7 (C-20, C-60),
115.9 (C-7), 116.6 (C-5), 120.2 (C-40), 120.6 (C-8), 127.0 (C-400),
127.6 (C-200, C-600), 128.3 (C-300, C-500), 129.8 (C-30, C-50), 132.3 (C-
6), 137.7 (C-100), 141.4, 142.0 (C-4a, C-8a), 162.0, 163.2, 164.0, 164.6
(COeCOO, COeCOO, C-10, C(]NH)NH2); HRMS (ESI) m/z calcd for
C25H24N3O6 [M þ H]þ 462.1665, found 462.1674; IR (KBr, v,
cm1): 3368, 1609, 1503, 1255, 844; HPLC: 96.1%, tr 9.5 min; Anal.
(C25H23N3O6  1/3CF3COOH) C, H, N.
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dihydro-1,4-benzodioxin-6-yl)amino)-2-oxoacetic acid (11b)
Synthesized from 10b (150 mg, 0.25 mmol) according to the
general procedure for synthesis of compounds 11aed; white
powder, yield 69 mg (60%); mp 294e297 C; [a]D ¼ 56.8 (c ¼ 2.0
in DMSO); 1H NMR (400MHz, DMSO-d6): d (ppm) 3.91 (dd, J¼ 11.2,
7.1 Hz, 1H, 3-CH2), 3.97 (dd, J ¼ 10.1, 5.9 Hz, 1H, CH2O), 4.08 (dd,
J ¼ 10.1, 5.5 Hz, 1H, CH2O), 4.31 (dd, J ¼ 11.2, 1.4 Hz, 1H, 3-CH2),
4.36e4.44 (m, 1H, 2-CH), 4.83 (d, J ¼ 15.3 Hz, 1H, NCH2), 4.89 (d,
J ¼ 15.3 Hz, 1H, NCH2), 6.73e6.85 (m, 3H, AreH8, AreH7, AreH5),
7.03 (d, J ¼ 8.8 Hz, 2H, AreH2’, AreH6’), 7.17e7.24 (m, 3H, Ph),
7.27e7.33 (m, 2H, Ph), 7.82 (d, J ¼ 8.8 Hz, 2H, AreH3’, AreH5’), 9.01
(bs, 2H, NH2), 9.96 (bs, 1H, NH); 13C NMR (101 MHz, DMSO-d6):
d (ppm) 50.6 (PheCH2), 64.4 (C-3), 66.8 (CH2O), 71.3 (2-C), 114.9 (C-
20, C-60), 116.1 (C-7), 117.3 (C-5), 120.1 (C-40), 120.9 (C-8), 127.4 (C-
400), 127.8 (C-200, C-600), 128.5 (C-300, C-500), 130.2 (C-30, C-50), 132.8 (C-
6), 136.3 (C-100), 142.5, 142.6 (C-4a, C-8a), 162.3, 163.0, 164.1, 164.5
(COCOO, COeCOO, C-10, C(]NH)NH2); HRMS (ESI) m/z calcd for
C25H24N3O6 [M þ H]þ 462.1665, found 462.1669; IR (KBr, v, cm1):
3311, 1610, 1500, 1267, 840; HPLC: 96.6%, tr 9.4 min; Anal.
(C25H23N3O6  1/15CF3COOH) C, H, N.
6.26. (R)-2-(benzyl(3-((4-carbamimidoylphenoxy)methyl)-2,3-
dihydro-1,4-benzodioxin-7-yl)amino)-2-oxoacetic acid (11c)
Synthesized from 10c (150 mg, 0.25 mmol) according to the
general procedure for synthesis of compounds 11aed; white
powder, yield 76mg (66%); mp 291e294 C; [a]D¼þ16.8 (c¼ 2.0 in
DMSO); 1H NMR (400 MHz, DMSO-d6): d (ppm) 3.86e3.99 (m, 2H,
3-CH2, CH2O), 4.08 (dd, J¼ 10.1, 5.3 Hz, 1H, CH2O), 4.30 (dd, J¼ 11.3,
1.8 Hz, 1H, 3-CH2), 4.35e4.45 (m, 1H, 2-CH), 4.82 (d, J ¼ 15.3 Hz, 1H,
NCH2), 4.90 (d, J ¼ 15.3 Hz, 1H, NCH2), 6.74e6.79 (m, 2H, AreH8,
AreH6), 6.81 (d, J ¼ 8.6 Hz, 1H, AreH5), 7.01 (d, J ¼ 8.8 Hz, 2H,
AreH2’, AreH6’), 7.16e7.26 (m, 3H, Ph), 7.27e7.33 (m, 2H, Ph), 7.83
(d, J ¼ 8.8 Hz, 2H, AreH3’, AreH5’), 9.06 (bs, 2H, NH2), 9.80 (bs, 1H,
NH); 13C NMR (101 MHz, DMSO-d6): d (ppm) 49.4 (PheCH2), 64.5
(C-3), 65.9 (CH2O), 71.0 (C-2), 114.7 (C-20, C-60), 115.2 (C-8), 116.9
(C-6), 118.9 (C-40), 120.1 (C-5), 126.9 (C-400), 127.3 (C-200, C-600), 128.3
(C-300, C-500), 129.8 (C-30, C-50), 135.5 (C-7), 137.8 (C-100), 141.1, 141.6
(C-4a, C-8a), 161.9, 163.2, 164.0, 164.2 (COeCOO, COeCOO, C-10, C(]
NH)NH2); HRMS (ESI)m/z calcd for C25H24N3O6 [Mþ H]þ 462.1665,
found 462.1668; IR (KBr, v, cm1): 3385, 1609, 1508, 1259, 845;
HPLC: 94.0%, tr 9.7 min; Anal. (C25H23N3O6  2/5CF3COOH  2/
5H2O) C, H, N.
6.27. (S)-2-(benzyl(3-((4-carbamimidoylphenoxy)methyl)-2,3-
dihydro-1,4-benzodioxin-7-yl)amino)-2-oxoacetic acid (11d)
Synthesized from 10d (150 mg, 0.25 mmol) according to the
general procedure for synthesis of compounds 11aed; yield
72 mg (62%); mp 290e293 C; [a]D ¼ 17.5 (c ¼ 2.0 in DMSO); 1H
NMR (400 MHz, DMSO-d6): d (ppm) 4.13 (dd, J ¼ 11.6, 7.9 Hz, 1H,
3-CH2), 4.34 (dd, J ¼ 10.9, 5.6 Hz, 1H, CH2O), 4.40 (dd, J ¼ 10.9,
3.6 Hz, 1H, CH2O), 4.48 (dd, J ¼ 11.6, 2.2 Hz, 1H, 3-CH2), 4.55e
4.65 (m, 1H, 2-CH), 4.88 (s, 2H, NCH2), 6.68 (dd, J ¼ 8.6, 2.5 Hz,
1H, AreH6), 6.80 (d, J ¼ 2.5 Hz, 1H, AreH8), 6.89 (d, J ¼ 8.6 Hz,
1H, AreH5), 7.18e7.37 (m, 7H, Ph, AreH2’, AreH6’), 7.83 (d,
J ¼ 8.9 Hz, 2H, AreH3’, AreH5’), 8.91 (s, 2H, NH2), 9.17 (s, 1H, NH);
13C NMR (101 MHz, DMSO-d6): d (ppm) 50.6 (PheCH2), 64.4 (C-
3), 66.8 (CH2O), 71.4 (C-2), 114.9 (C-20, C-60), 116.1 (C-8), 117.3 (C-
6), 120.1 (C-40), 120.7 (C-5), 127.4 (C-400), 127.8 (C-200, C-600), 128.5
(C-300, C-500), 130.2 (C-30, C-50), 133.0 (C-7), 136.3 (C-100), 142.5,
142.6(C-4a, C-8a), 162.3, 163.1, 164.2, 164.5 (COeCOO, COeCOO,
C-10, C(]NH)NH2); HRMS (ESI) m/z calcd for C25H24N3O6[M þ H]þ 462.1665, found 462.1684; IR (KBr, v, cm1): 3309,
1609, 1492, 1262, 839; HPLC: 96.2%, tr 9.7 min; Anal.
(C25H23N3O6  1/11CF3COOH) C, H, N.
6.28. Docking studies
The binding modes of the ligands to both targets were studied
by Autodock 4.0 [53]. The energetically most favorable con-
formationwas found for each stereoisomer with HyperChem, using
the semiempirical method MNDO. All amide bonds had trans
conﬁguration and weremarked as non-rotatable. Compounds were
protonated on the basic center (amidino, or amino group) and were
assigned with a negative charge on the acidic center (carboxylic
group). The crystal structures of thrombin (PDB entry code: 1KTS)
[48] and GP IIb/IIIa (PDB entry code: 2VDM) [49] were extracted
from the Brookhaven Protein Database. The PDB crystal structures
were prepared for docking by removing water molecules and li-
gands. In the case of 2VDM, the magnesium ion in the active site
was retained and manually assigned a charge of þ2 and solvation
parameters. The ligands were docked into a restricted box centered
in the active site (22 Å  22 Å  22 Å). For the global search using
the LGA (Lamarckian genetic algorithm), the size of the initial
random population was 250 individuals, the maximal number of
energy evaluations 1.25  106, the maximal number of generations
500, the number of top individuals that survived into the next
generation (the elitism) 1, the probability that a gene would un-
dergo a random change 0.02, and the crossover probability 0.80.
The average of theworst energywas calculated over awindowof 10
generations. For a purely local search, the pseudo Solis and Wets
methodwas used, whereas the Solis andWets methodwas used for
the LGA part of the local search. The parameters used for local
search in both cases were a maximum of 1000 iterations per local
search, the probability of performing a local search on an individual
was 1.0, the maximal number of consecutive successes or failures
before doubling or halving the step size of the local search was 4,
and the lower bound on the step size, 0.01, was the termination
criterion for the local search. A total of 250 dockings were per-
formed, and ligands with RMSD less than 1 were joined in clusters.
The ligand with the lowest docked energy was chosen for inter-
preting the docking results.
6.29. Biochemical evaluation
6.29.1. Enzyme assay for inhibition of serine proteases
The enzymic amidolytic method for determining inhibition of
thrombin, factor Xa and trypsin was based on the spectrophoto-
metric determination of absorbance of the product formed after
amide bond cleavage of a chromogenic substrate in the presence of
the enzyme.Ki, which is a quantitativemeasure of inhibitor potency,
was determined from the kinetics of substrate hydrolysis with and
without the addition of the inhibitor. Measurements (spectropho-
tometer, BioTek Synergy H4) were performed in 96-well microtiter
plates with a ﬁnal volume of 200 mL. Thrombin was tested in a ﬁnal
concentration of 0.5 NIH E/mL with the substrate S-2238 (Chro-
mogenix) at 20 and 40 mM ﬁnal concentration, and factor Xa at the
ﬁnal concentration of 1 mBAEE E/mL with the substrate S-2222
(Chromogenix) at 100 and 200 mM ﬁnal concentrations.
Trypsin was assayed at a ﬁnal concentration of 0.5 nkat/mL
using the substrate S-2222 (Chromogenix) at 50 and 100 mM ﬁnal
concentrations. Inhibitors were dissolved in DMSO (concentration
of stock solutions, 10 mmol/L) and diluted with distilled water to
concentrations from 0.5 to 100 mM. Reaction rates were measured
in the presence and the absence of the inhibitor. Then 50 mMHBSA
buffer, the 50 mM solution of each inhibitor concentration (or of
HBSA buffer in case of measurement without inhibitor), and
M. Ilic et al. / European Journal of Medicinal Chemistry 62 (2013) 329e340 33950 mM of enzyme solution were pipetted into the microtiter wells.
The plate was incubated for 15 min at 25 C and 50 mL of chro-
mogenic substrate then added. Absorbance at 405 nm was
measured every 10 s at 25 C. Measurements were carried out in
triplicate with three concentrations of the inhibitor and two con-
centrations of the substrate. For every combination of concentra-
tions, Ki was calculated from the change of absorbance in the initial,
linear part of the curve according to the method of Cheng and
Prusoff [54] and the ﬁnal result was given as their average value.
Dabigatran (thrombin, Ki ¼ 6.3  1.1 nM) was used as control.
6.29.2. Inhibition of in vitro binding of ﬁbrinogen to isolated GPIIb/
IIIa and GPV/IIIa receptors
Binding afﬁnities to GPIIb/IIIa and GPV/IIIa receptor were
measured by a solid-phase competitive displacement assay. Human
ﬁbrinogen (100 mg) was dissolved in aqueous NaCl (0.3 M, 5 mL) at
30 C and then it was diluted with 0.1 M NaHCO3 in water to a ﬁnal
concentration of 1 mg/mL. Biotin N-hydroxysuccinimide ester
(2 mg) was dissolved in DMF (2 mL) and added to 6 mL of ﬁbri-
nogen solution. The reaction mixture was incubated for 90 min at
30 C and dialyzed for 3 h at room temperature against buffer 1 (3 L,
20 mM Tris, 150 mM NaCl, pH 7.4). After dialysis, the solution was
centrifuged for 5 min at 5400 rpm and Tween-20 (0.005%) added to
give the stock solution. Human integrin (10 mL of GPIIb/IIIa receptor
solution (Calbiochem), 1 mL of GPV/IIIa receptor solution (Calbio-
chem)) was diluted in 10.2mL of buffer 2 (50mMTris,150mMNaCl,
1 mM CaCl2, 1 mMMgCl2, 1 mMMnCl2, pH 7.4) and adsorbed to 96-
well (100 mL/well) high-binding microtiter plates (Greiner, Lumi-
trac 600) overnight at 4 C. Nonspeciﬁc receptor-binding sites were
blocked with 1% BSA in buffer 2 (200 mL/well). Following incubation
for 1 h at room temperature, the plates were washed twice with
buffer 3 (buffer 2 containing 0.1% Tween-20). The potential antag-
onists were serially diluted with buffer 2 containing 0.1% of BSA and
test solutions added (50 mL/well) together with biotinylated ﬁbri-
nogen (50 mL/well, 1:42 dilution of stock solution in buffer 2 con-
taining 0.1% of BSA) to each well. The plates were incubated for 2 h
at room temperature, and then washed twice with buffer 3.
Peroxidase-conjugated antibiotin goat antibody (100 mL/well of
a 1:1000 dilution of purchased solution (Calbiochem) in buffer 2
containing 0.1% of BSA) was added to each well and incubated for
another hour. The microtiter plates were washed three times with
buffer 3. Finally, chemiluminescent substrate (POD, Roche Di-
agnostics, Boehringer Mannheim) (100 mL/well) was added and the
luminescence measured with a BioTek Synergy H4 multimode
research reader three times over 10 min. Positive controls received
no inhibitors, while negative controls received no receptor. Tir-
oﬁban (IC50(GPIIb/IIIa) ¼ 0.37  0.11 nM) was used as the internal
standard. Assays were performed in duplicate and repeated at least
three times on various days. The mean experimental data were
ﬁtted to the sigmoid model and IC50 values calculated from the
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